Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 632

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 632
---
 (the “Project Agreement”). In connection with the detailing services, the Project Agreement provides that the
vendor will provide Scilex Pharma with full-time sales representatives who shall detail the Product by making calls pursuant to a call plan on targets. In connection with the sales operation services, the vendor will provide certain services
required for the initial implementation and ongoing operation of the sales force.

In May 2025, Scilex Pharma and the vendor entered into a work order in
which the parties agreed to convert substantially all of the sales representatives allocated under the Project Agreement to become employees of the vendor. The work order shall be in effect and remain in effect until the thirty-six months anniversary of the Deployment Date, as set forth in accordance with the terms of the Project Agreement, which is June 3, 2025, or until terminated in accordance with the terms of the Project
Agreement or unless extended as provided therein (the “Term”). The Term may be extended for additional periods of one (1) year (each, an “Additional Term”) upon the mutual written agreement of the parties not less than
sixty (60) days before the end of the Term or any Additional Term. Scilex Pharma paid a one-time implementation fee of $72 thousands associated with the operational setup and the recruiting of the sales
representatives and will pay fixed monthly fee of $1.2 million for year one and $1.3 million for each of year two and year three.

Pursuant to
the terms set forth in the Project Agreement, either party may terminate this work order without cause upon ninety (90) days prior written notice to the other party; provided, however, that such termination by Scilex Pharma may not occur prior
to the twelve (12) month anniversary of the Deployment Date.

Investment Agreement

In August 2025, Scilex Bio entered into an Investment Commitment Agreement (the “Investment Agreement”) with PA OPS Investor LLC (“Investor
LLC”). Pursuant to the terms of the agreement, the Company committed to providing $2.5 million in future funding, contingent upon Investor LLC successfully identifying and acquiring a target company for investment by December 31,
2025. As of September 30, 2025, no such acquisition had occurred, and no funding has been provided. Accordingly, this commitment is not reflected in the consolidated financial statements, but represents potential future cash outflows.

Litigation

From time to time, the Company
may be subject to claims and legal